Serum levels of omentin and visfatin in patients with metabolic syndrome
Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction Metabolic Syndrome (MetS) is a global health concern characterised by cardiometabolic risk factors, dysregulated adipokine signalling and inflammation. The study aimed to assess the serum levels of omentin and visfatin in patients with metabolic syndrome.Methods The 84-subject hospital-based case-control study included 18–55 years, both genders. Anthropometry, medical history, fasting plasma glucose (FPG), lipid profile, and HOMA-IR were collected. Insulin, omentin, and visfatin were measured using ELISA.Results Omentin and visfatin levels significantly differed between groups (p < 0.05). The median omentin levels were 50.74 and 45.25; visfatin levels were 0.064 and 0.001, respectively. Omentin correlated with waist circumference, blood pressure, and FPG in controls, while visfatin correlated with HDL and BMI among cases (p < 0.05). Omentin and visfatin were elevated in cases. However, no significant correlation between omentin and visfatin with lipid parameters could be established.Conclusion Omentin and visfatin levels varied significantly between metabolic syndrome and controls; their correlation with MetS criteria was not significant.
Authors: Anita Sherly A, Rukmini M.S, Anupama Hegde, Arun S, Himani Kotian
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4409372148